Brief: Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer

Galectin Therapeutics

12/10/2022 12:59

Oct 12 (Reuters) - Galectin Therapeutics Inc  GALT.O :
    * GALECTIN THERAPEUTICS RECEIVES FDA APPROVAL TO PROCEED
WITH
COMBINATION IMMUNOTHERAPY TRIAL IN HEAD AND NECK CANCER
    * GALECTIN - ALSO RECEIVED STUDY MAY PROCEED LETTER FOR A
PHASE 2
CLINICAL TRIAL FOR EFFICACY, SAFETY OF BELAPECTIN IN COMBINATION
WITH PEMBROLIZUMAB
    * GALECTIN - IND APPLICATION FOR BELAPECTIN IN COMBINATION
WITH A
CHECKPOINT INHIBITOR FOR TREATMENT OF HEAD AND NECK CANCER FILED
WITH THE FDA

Further company coverage:  GALT.O 
 ((Reuters.Briefs@thomsonreuters.com;))